More than two-thirds of biotherapeutics are glycosylated proteins, which includes the therapeutically important category of monoclonal antibodies. The development and manufacturing of these potentially life-changing treatments, however, carries a high risk of failure and is technically challenging and expensive. Glycosylation is a critical product quality attribute that impacts on the efficacy and safety of glycosylated biotherapeutics and, therefore, must be characterized and monitored throughout product development and manufacturing processes.
Key Learning Objectives:
Review a simplified, rapid, high-throughput and cost-effective platform for characterization and monitoring of the glycosylation profile throughout development and manufacturing
Learn about a novel approach for safety and potency assurance in biopharmaceuticals
Use of Octet® platform for high-throughput detection of glycans in biopharmaceutical samples
Available throughout the year!